Billiontoone, Inc. (NASDAQ:BLLN) Given Consensus Rating of “Hold” by Brokerages

Shares of Billiontoone, Inc. (NASDAQ:BLLN) have received an average recommendation of “Hold” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $125.8750.

Several research firms have recently issued reports on BLLN. BTIG Research dropped their price objective on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Guggenheim began coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. Wall Street Zen cut Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research cut shares of Billiontoone from a “hold” rating to a “strong sell” rating in a research note on Monday, August 31st. Finally, Canaccord Genuity Group began coverage on Billiontoone in a research note on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 target price for the company.

Insider Transactions at Billiontoone

In other news, insider Shan Sakakibara sold 4,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $140.21, for a total transaction of $560,840.00. Following the transaction, the insider owned 200,000 shares of the company’s stock, valued at $28,042,000. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Oguzhan Atay sold 32,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $136.95, for a total value of $4,450,875.00. Following the completion of the transaction, the chief executive officer owned 20,000 shares in the company, valued at approximately $2,739,000. This represents a 61.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 164,133 shares of company stock valued at $19,719,146 over the last quarter. Corporate insiders own 50.22% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Adams Street Partners LLC acquired a new stake in Billiontoone during the 4th quarter worth $140,063,000. Price T Rowe Associates Inc. MD bought a new position in Billiontoone in the fourth quarter valued at approximately $39,717,000. JPMorgan Chase & Co. bought a new stake in Billiontoone in the 4th quarter valued at $32,078,000. Wasatch Advisors LP acquired a new position in shares of Billiontoone during the first quarter worth about $29,179,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Billiontoone during the 4th quarter worth approximately $18,631,000.

Billiontoone Stock Performance

Shares of BLLN opened at $99.06 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. The company’s fifty day moving average price is $112.97 and its 200 day moving average price is $95.64. The company has a market capitalization of $4.67 billion and a PE ratio of 141.51. Billiontoone has a one year low of $61.96 and a one year high of $150.44.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The business had revenue of $109.45 million during the quarter. As a group, analysts expect that Billiontoone will post 0.83 earnings per share for the current year.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.